Drugs / Ex vivo-expanded NK cell enriched lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02370017 | Feb 2015 → Aug 2018 | non-small cell lung carcinoma | The Catholic University of Korea | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex vivo-expanded NK cell enriched lymphocytes | “ANKL(Ex vivo-expanded NK cell enriched lymphocytes)” NCT02370017 ↗ |
| Known as | ANKL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370017 ↗ |
| Modality | Cell therapy | “Ex vivo-expanded NK cell enriched lymphocytes” NCT02370017 ↗ |
| Route | Intravenous | “ANKL (2x10\*9) from peripheral blood 32ml is administered rapidly iv 12-36hr after each chemotherapeutic agents” NCT02370017 ↗ |